Breaking News Instant updates and real-time market news.

MRK

Merck

$80.25

1.03 (1.30%)

16:56
06/03/19
06/03
16:56
06/03/19
16:56

Merck confirms FDA approval of Zerbaxa indication

Merck announced that the U.S. Food and Drug Administration has approved Merck's supplemental New Drug Application for the use of ZERBAXA for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Haemophilus influenzae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Serratia marcescens. The sNDA for ZERBAXA had previously been designated Priority Review status by the FDA. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. This expanded use is based on results of the pivotal Phase 3 ASPECT-NP trial that compared ZERBAXA 3g intravenously every 8 hours to meropenem for 8 to 14 days for the treatment of adult patients with HABP/VABP. "We are grateful to all of the patients who participated in the studies which led to the approval of ZERBAXA for the treatment of HABP/VABP," said Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. "This approval reflects Merck's longstanding commitment to helping alleviate the burden of infectious diseases, including serious infections caused by Gram-negative pathogens."

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 16

    Jul

  • 30

    Jul

  • 06

    Aug

  • 20

    Sep

MRK Merck
$80.25

1.03 (1.30%)

05/21/19
MSCO
05/21/19
NO CHANGE
Target $84
MSCO
Overweight
Morgan Stanley not lowering Keytruda projections despite Merck disappointment
After Merck announced that Keytruda monotherapy failed to beat chemotherapy in a Phase 3 triple negative breast cancer, or TNBC, trial, Morgan Stanley analyst David Risinger said he is not r lowering his Keytruda projections as he is hopeful that the drug can succeed in KN-355, another TNBC trial, later this year. In that trial, a combination of Keytruda plus chemo will be investigated in first-line TNBC, noted Risinger, who has an Overweight rating and $84 price target on Merck shares.
05/22/19
GUGG
05/22/19
NO CHANGE
GUGG
Buy
Guggenheim says Peloton Therapeutics a good strategic fit for Merck
Guggenheim analyst Seamus Fernandez said he thinks Peloton Therapeutics is a good strategic fit for Merck citing the "rational targeting" of a resistance mechanism to VEGF-TKIs commonly used in the treatment of Renal Cell Carcinoma, or RCC. Fernandez, who sees the transaction being minimally dilutive and having no impact on 2019 adjusted EPS guidance, keeps a Buy rating on Merck shares.
05/28/19
GSCO
05/28/19
INITIATION
Target $85
GSCO
Neutral
Merck initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Terence Flynn started Merck with a Neutral rating and $85 price target. The analyst projects the company's earnings and revenue growth through 2022 will be in-line with consensus. As such, he views the stock as fairly valued.
05/30/19
GUGG
05/30/19
NO CHANGE
GUGG
Buy
Array BioPharma could be seen as target after 'de-risking' data, says Guggenheim
Guggenheim analyst Michael Schmidt said Array Biopharma (ARRY) may be perceived by investors as a theoretical acquisition target following the disclosure of Phase 3 interim results of Braftovi/Mektovi in BRAF+ colorectal cancer, which he views as positive and a "de-risking event." 67% of announced acquisitions in oncology with a comparable market cap to Array had what he would consider major pipeline de-risking events in the 6 months prior to their deal announcements, Schmidt tells investors. Merck (MRK) and Pfizer (PFE) "seem to have most bandwidth for a deal," said Schmidt, who added that those two along with Bristol-Myers (BMY), AstraZeneca (AZN) and Roche (RHHBY) scored highest as possible large cap theoretical acquirers of Array in his analysis. Schmidt raised his price target on Array Biopharma shares to $38 from $37, though his analysis suggests a potential $40-$50 acquisition price if the company were to be bought.

TODAY'S FREE FLY STORIES

KDMN

Kadmon

$3.56

-0.155 (-4.18%)

20:59
11/13/19
11/13
20:59
11/13/19
20:59
Syndicate
Kadmon 26M share Spot Secondary priced at $3.40 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

UBER

Uber

$26.70

(0.00%)

20:17
11/13/19
11/13
20:17
11/13/19
20:17
Hot Stocks
Uber chairman buys 35K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 21

    Nov

  • 04

    Dec

ALPN

Alpine Immune Sciences

$2.49

-0.06 (-2.35%)

19:47
11/13/19
11/13
19:47
11/13/19
19:47
Recommendations
Alpine Immune Sciences analyst commentary  »

Alpine Immune Sciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

HPQ

HP Inc.

$19.54

-0.005 (-0.03%)

19:45
11/13/19
11/13
19:45
11/13/19
19:45
Hot Stocks
HP Inc. raises quarterly dividend to 17.6c from 16.0c per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

RETA

Reata Pharmaceuticals

$187.00

4.48 (2.45%)

19:18
11/13/19
11/13
19:18
11/13/19
19:18
Syndicate
Reata Pharmaceuticals 2.4M share Secondary priced at $183.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

19:15
11/13/19
11/13
19:15
11/13/19
19:15
General news
Breaking General news story  »

Philadelphia Federal…

19:15
11/13/19
11/13
19:15
11/13/19
19:15
General news
Breaking General news story  »

Philadelphia Federal…

BCRX

BioCryst

$1.60

-0.185 (-10.39%)

19:13
11/13/19
11/13
19:13
11/13/19
19:13
Syndicate
BioCryst 37.93M share Secondary priced at $1.45 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

, GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

19:03
11/13/19
11/13
19:03
11/13/19
19:03
Periodicals
U.S. lawmaker frustrated with Google's bid to buy Fitbit, Reuters says »

U.S. Representative David…

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

FB

Facebook

$193.20

-1.27 (-0.65%)

AMZN

Amazon.com

$1,753.84

-24.49 (-1.38%)

AAPL

Apple

$264.52

2.63 (1.00%)

FIT

Fitbit

$6.86

-0.105 (-1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 20

    Nov

PING

Ping Identity

$16.50

-0.25 (-1.49%)

, SNDL

Sundial Growers

$3.62

-0.16 (-4.23%)

18:51
11/13/19
11/13
18:51
11/13/19
18:51
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Ping…

PING

Ping Identity

$16.50

-0.25 (-1.49%)

SNDL

Sundial Growers

$3.62

-0.16 (-4.23%)

PUMP

ProPetro Holding

$7.34

-0.36 (-4.68%)

PRSP

Perspecta

$27.79

-0.18 (-0.64%)

HI

Hillenbrand

$31.53

-1 (-3.07%)

CPA

Copa Holdings

$107.71

1.89 (1.79%)

PSNL

Personalis

$10.92

0.745 (7.33%)

TRQ

Turquoise Hill

$0.46

-0.006 (-1.29%)

CATS

Catasys

$14.60

-0.47 (-3.12%)

LTRX

Lantronix

$3.15

0.06 (1.94%)

SLGG

Super League Gaming

$3.06

0.07 (2.34%)

BZH

Beazer Homes

$14.67

0.21 (1.45%)

CSCO

Cisco

$48.44

0.06 (0.12%)

TTEK

Tetra Tech

$88.38

1.24 (1.42%)

NTAP

NetApp

$60.04

-0.08 (-0.13%)

FLGT

Fulgent Genetics

$13.62

0.11 (0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 14

    Nov

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

  • 04

    Dec

  • 09

    Dec

  • 10

    Dec

  • 12

    Dec

  • 14

    Nov

BZH

Beazer Homes

$14.67

0.21 (1.45%)

18:49
11/13/19
11/13
18:49
11/13/19
18:49
Earnings
Beazer Homes reports Q4 EPS 8c, two estimates 51c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

HT

Hersha Hospitality

$13.84

-0.23 (-1.63%)

18:46
11/13/19
11/13
18:46
11/13/19
18:46
Hot Stocks
Hersha Hospitality CEO: Airnb has definitely had an impact »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

FICO

Fair Isaac

$336.80

2.56 (0.77%)

18:40
11/13/19
11/13
18:40
11/13/19
18:40
Hot Stocks
Fair Isaac director sells 6K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PUMP

ProPetro Holding

$7.34

-0.36 (-4.68%)

18:33
11/13/19
11/13
18:33
11/13/19
18:33
Hot Stocks
ProPetro discloses U.S. SEC probe »

ProPetro has filed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 14

    Nov

DXCM

DexCom

$202.81

-3.35 (-1.63%)

, WBA

Walgreens Boots Alliance

$62.24

-0.48 (-0.77%)

18:25
11/13/19
11/13
18:25
11/13/19
18:25
Hot Stocks
DexCom CEO: The type 2 diabetes business is just getting started »

In an interview on…

DXCM

DexCom

$202.81

-3.35 (-1.63%)

WBA

Walgreens Boots Alliance

$62.24

-0.48 (-0.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 22

    Nov

EQS

Equus II Inc

$1.55

(0.00%)

18:19
11/13/19
11/13
18:19
11/13/19
18:19
Hot Stocks
Equus reports Q3 NAV per share of $3.63 »

Equus Total Return…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SSYS

Stratasys

$18.35

-2.39 (-11.52%)

18:04
11/13/19
11/13
18:04
11/13/19
18:04
Recommendations
Stratasys analyst commentary at Piper Jaffray »

Stratasys price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

GLD

SPDR Gold Shares

$137.98

0.56 (0.41%)

18:03
11/13/19
11/13
18:03
11/13/19
18:03
Hot Stocks
SPDR Gold Shares holdings fall to 896.77MT from 897.09MT »

This is the second…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPA

Copa Holdings

$107.71

1.89 (1.79%)

17:57
11/13/19
11/13
17:57
11/13/19
17:57
Hot Stocks
Copa Holdings reports October capacity down 4.8%, traffic down 1.4% »

Copa Holdings released…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 03

    Dec

CCI

Crown Castle

$131.34

0.67 (0.51%)

17:51
11/13/19
11/13
17:51
11/13/19
17:51
Hot Stocks
Crown Castle chairman buys 10.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

, GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

17:48
11/13/19
11/13
17:48
11/13/19
17:48
Periodicals
Google confirms several features not available on Stadia at launch, Kotaku says »

During an AMA on Reddit,…

GOOG

Alphabet

$1,298.00

-0.77 (-0.06%)

GOOGL

Alphabet Class A

$1,296.00

-1.18 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAESY

BAE Systems

$0.00

(0.00%)

17:44
11/13/19
11/13
17:44
11/13/19
17:44
Hot Stocks
BAE Systems awarded maximum $270.6M Navy contract modification »

BAE Systems was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HBT

HBT Financial

$16.99

0.18 (1.07%)

17:38
11/13/19
11/13
17:38
11/13/19
17:38
Hot Stocks
HBT Financial director Patrick Busch buys over 13K shares of company stock »

HBT Financial director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMO

Thermo Fisher

$299.90

3.82 (1.29%)

, QGEN

Qiagen

$35.52

3.26 (10.11%)

17:38
11/13/19
11/13
17:38
11/13/19
17:38
Periodicals
Thermo Fisher considering purchase of Qiagen, Bloomberg reports »

Thermo Fisher (TMO) is…

TMO

Thermo Fisher

$299.90

3.82 (1.29%)

QGEN

Qiagen

$35.52

3.26 (10.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 07

    Dec

AOBC

American Outdoor Brands

$7.90

0.22 (2.86%)

17:36
11/13/19
11/13
17:36
11/13/19
17:36
Conference/Events
American Outdoor Brands to hold a conference call »

President & CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.